New Delhi, (PTI) A therapy combining cell-killing and immune-stimulating drugs are safe and effective in extending survival for patients with gliomas, a highly aggressive form of brain cancer, according to a study published in The Lancet Oncology journal.
Given gliomas’ poor prognosis and limited response to treatments like chemotherapy and radiation, the team looked to using the protein Flt3L to recruit immune cells, typically absent from the brain. These immune cells are required to kick start a more effective cancer immune response.
“Being able to move a novel therapy from bench to bedside in such a streamlined fashion is exciting, and represents a tour-de-force in translational medicine,” said Oren Sagher, a professor of neurosurgery at the University of Michigan (U-M), US.
